Imaging has become an indispensable tool in cancer research, clinical trials and medical practice. Over the past few decades, there has been a huge increase in the number of molecular imaging technologies and their applications.
In the 1940s the average five-year survival rate for all breast cancer (BC) patients was 53%. As a result of advances in cancer treatment, survival rates in patients with BC have increased dramatically.
Over the past few decades, there has been a sharp increase in cancer survivors due to advancements in cancer therapeutics and early detection. Many of these survivors are in their reproductive years, and planning a family is at the top of their priority list.
Lose teeth, oral abscesses and inexplicable ear ache might be signs and of head and neck squamous cell carcinoma (HNSCC), says radiation oncologist, Dr Robert de Müelenaere of De Müelenaere Oncology. HNSCC ranks sixth among the most common cancers worldwide with over 500 000 new cases reported each year.
The United States Preventive Services Task Force (USPSTF) published their updated recommendation statement on screening for cervical cancer (CC) in the August issue of the Journal of the American Medical Association.
Radiotherapy for localised prostate cancer is a standard option, but unfortunately a significant number of patients will experience prostate-specific antigen failure after treatment.
MEDICAL CHRONICLE OCTOBER CPD 2 of 4: Breast cancer is the most common of all cancers in women, with the lifetime risk of getting breast cancer in South African women being 1 out of every 26.
Advances in the treatment of potentially life-threatening diseases such as cancer, are often accompanied by side effects, which can severely affect patients’ quality of life (QOL). As a result, some patients discontinue treatment.
In recognising the impact that Pembrolizumab would have in oncology treatment, MSD received regulatory approval by the Medicines Control Council (now South African Health Products Regulatory Authority) in South Africa.